Half the battle won with new child-friendly TB drugs:

What's the other half?

CNS Webinar
15 December, 2015

Dr Brenda Waning
Chief, Global Drug Facility (GDF)

The other half: Making sure these medicines get to

all those who need them as quickly as possible
What needs to happen:
1. Increase awareness & demand
2. Secure financing
3. Support countries to adopt new medicines
4. Procure medicines & begin treatment
5. Manage market supply & demand

1. Increase awareness of & demand for the pediatric

TB formulations
Target audiences: practitioners, caregivers, advocates, and policy
makers at global and national levels
Conduct widespread awareness campaigns to ensure key decision
makers & consumers know these new medicines exist;
Educate key decision makers & consumers on the benefits &
advantages of the new formulations
Garner political will to aggressively treat children: new formulations
facilitate treatment; opportunity to reset goals & expectations
Utilize policy levers, where appropriate, to increase demand
Donors & other third-party payors can institute policies that require or
encourage countries to switch to new formulations

2. Secure adequate financing to ensure countries have

funds to purchase the new pedi TB formulations
Advocate for budget space to purchase the new formulations in
countries who are funding their national treatment programs;

Support countries who may need to reprogram or reallocate Global

Fund budgets to create fiscal space to purchase these new
medicines
Consider increasing targets for pediatric TB treatment; TB Situation Room

Ensure that countries transitioning from Global Fund to domestic

financing continue to use these optimized formulations

Secure additional funding to provide grants to countries for the

initial conversion (bridge grants)

3. Support countries to adopt the new pedi TB

formulations
Provide technical assistance & capacity building:
Revision of national pediatric TB treatment guidelines
Supply planning on how to optimally phase-out the old products and phasein the new products (inventory management, ordering frequency)
Quantification, forecasting, early warning systems

Mechanisms & resources to provide TA & capacity building:

Missions to countries
Partner mobilization
Regional and country workshops and trainings for
national TB treatment programs, partners, consultants

4. Procure the medicines and begin treating children

with the new pedi TB formulations
New Pediatric TB
formulations are available
for purchase via the Global
Drug Facility
Email: GDF@stoptb.org

http://www.stoptb.org/gdf/

5. Actively monitor and manage the fragile, pediatric

TB medicines market
Establish systems to actively monitor the supply and demand sides of the market
To ensure a consistent, uninterrupted supply of medicines is available in countries;
To ensure medicines are not wasted;

Monitor demand in countries, develop global forecasts, and coordinate

production planning with manufacturers
Consolidate demand to the fewest number of formulations
Conduct coordinated or pooled procurement, where possible
Establish pedi TB procurement working group similar to pedi ARV working group

Develop medicines stockpile

Rapid response to emergency orders, reduce lead times, and improve production planning

Identify and attract additional supplier(s) to develop the new formulations

Implement interventions to decrease prices
Monitor & evaluate product introduction
Share challenges, progress with all stakeholders via regular market management meetings

The Global Drug Facility is Uniquely Positioned to

Support New TB Product Introduction
GDF is a Geneva-based initiative of the Stop TB Partnership (2001),
hosted by UNOPS
One-stop shop for TB medicines & diagnostics:
Procurement
First-line drugs (FLDs) since 2001; second-line drugs (SLDs), pediatric
meds, and diagnostics since 2008
Sole supplier of SLDs for the Global Fund

Technical assistance, capacity building

Procurement & supply chain management

Support for new product introduction

Currently supporting bedaquiline introduction

Market management & coordination

Thank You!

Contact Info Brenda Waning:

Chief, Global Drug Facility
brendaw@stoptb.org